Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,105 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Kidney Disease (CKD) Clear all
Completed No phase listed Observational

Procalcitonin and Brain Natriuretic Peptides in Patients With Chronic Kidney Disease.

NCT03698877
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests
Diagnostic Test
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease

NCT02031770
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease
Interventions
Sodium bicarbonate, Control
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease

NCT03579693
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia, Frailty
Interventions
CoQ10, Nicotinamide riboside, Placebo
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

NCT02273726
View directory record Official record
Conditions
CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin Alfa, Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
74
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 7, 2026, 4:08 AM EDT
Not listed Phase 2 Interventional

Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease

NCT04258397
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pirfenidone, matching placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 7, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate

NCT02743650
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium bicarbonate
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 7, 2026, 4:08 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

NCT01464190
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

NCT02940860
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
141
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 7, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

NCT06374277
View directory record Official record
Conditions
Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
Interventions
Med AAAction intervention
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Knoxville, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

NCT01950819
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Interventions
Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus

NCT05342545
View directory record Official record
Conditions
Chronic Kidney Diseases, Type2Diabetes
Interventions
Alert-based computerized decision support
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 7, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional

CommunityRx-Kidney Health

NCT07237295
View directory record Official record
Conditions
Chronic Kidney Disease (Stages 1-4)
Interventions
CommunityRx-Kidney Health
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Beulaville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Enrolling by invitation Not applicable Interventional

Pro-social Power Training Activity for Aging and Well-being With Chronic Kidney Disease

NCT06089057
View directory record Official record
Conditions
Lower Extremity Muscle Strength
Interventions
Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease, Attention Control for Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

NCT00863707
View directory record Official record
Conditions
Kidney Diseases, Coronary Artery Disease
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
41
States / cities
Anniston, Alabama • Little Rock, Arkansas • Bell Gardens, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

NCT00506441
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions
MCI-196, Placebo
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
38
States / cities
Glendale, Arizona • Tempe, Arizona • Hot Springs, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed No phase listed Observational

OPTIMISE-CKD Drug Utilization

NCT05932901
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,682,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneota, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 7, 2026, 4:08 AM EDT
Completed No phase listed Observational

Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data

NCT04882813
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Dapagliflozin, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
87,727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

NCT01628120
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
115
States / cities
Azusa, California • Bakersfield, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 7, 2026, 4:08 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

A Study of Renal Microvessel Imaging for Chronic Kidney Disease

NCT05764642
View directory record Official record
Conditions
Healthy, Chronic Kidney Diseases
Interventions
Definity, Super-resolution ultrasound imaging
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Not yet recruiting Phase 4 Interventional

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

NCT07155694
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone 10 MG, Empagliflozin 10 MG
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 7, 2026, 4:08 AM EDT
Completed No phase listed Observational

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

NCT06122961
View directory record Official record
Conditions
Cardiovascular Risk, Heart Failure, Chronic Kidney Disease
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
18,198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Fremont, California • McKinney, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 7, 2026, 4:08 AM EDT